Key Takeaways J&J will report third-quarter 2025 results on Oct. 14, kicking off the earnings season for pharma players.Sales growth is expected from Darzalex, Tremfya, Erleada and new drugs like Carvykti and Tecvayli.Stelara faces steep biosimilar competition, while MedTech faces China-related headwinds.Johnson & Johnson (JNJ) will begin the earnings season for the drug & biotech sector when it reports its third-quarter 2025 results on Oct. 14. The Zacks Consensus Estimate for third-quarter sales and earni ...

Johnson & Johnson is set to release its quarterly earnings with an estimated EPS of $2.78 and projected revenue of $23.7 billion.The company's stock has increased by 31% this year, outperforming the S&P 500's 14% rise.JNJ has a history of outperforming earnings estimates, with an average earnings surprise of 5.96% over the last two quarters.Johnson & Johnson (NYSE:JNJ) is a leading global healthcare company known for its wide range of products, including pharmaceuticals, medical devices, and consumer health ...

Key Takeaways Halozyme will acquire Elektrofi for $750M plus up to $150M in milestone payments.The deal adds Elektrofi's Hypercon technology, expanding Halozyme's delivery capabilities.HALO reaffirmed its 2025 revenue outlook, expecting $1.28B-$1.36B in total revenues.Halozyme Therapeutics (HALO) has collaboration deals related to its ENHANZE technology with large pharma companies that use the technology for the development of subcutaneous (“SC”) formulations of their various approved drugs. These deals gen ...

Key Takeaways Pfizer's deal with Trump cuts drug prices, boosts U.S. investment and lifts pharma sector sentiment.Investor optimism grows as major drugmakers eye similar tariff-free pricing agreements with Trump.J&J, Bayer and Novartis show strong growth momentum, making them attractive pharma investment picks.Late last month, Pfizer (PFE) announced a landmark deal with the Trump administration to cut drug prices and expand U.S. innovation and manufacturing.Under the deal, Pfizer agreed to slash prices of s ...

Johnson & Johnson (NYSE:JNJ) is included among the 13 Most Profitable Dividend Stocks to Buy Right Now. Johnson & Johnson (JNJ): A Cornerstone Among the Most Profitable Dividend Stocks Johnson & Johnson (NYSE:JNJ) is one of America’s most recognizable healthcare companies, with operations that now center on pharmaceuticals and medical devices. After spinning off its consumer health unit, which included familiar names like Tylenol, Neutrogena, and Listerine, into a separate company called Kenvue, the comp ...

Key Takeaways J&J projects stronger Innovative Medicine sales in H2 despite Stelara's LOE.Higher demand for Darzalex, Tremfya, and Erleada likely supported segment growth in Q3.Stelara biosimilars and IRA's Part D redesign continue to put pressure on J&J's drug sales.Johnson & Johnson (JNJ) , through its Innovative Medicine division, markets several blockbuster drugs across diverse therapeutic areas, including neuroscience, cardiovascular and metabolism, immunology, oncology, pulmonary hypertension (PH), an ...

Core Insights - Johnson & Johnson (J&J) has increased its dividend for 63 consecutive years, positioning itself as a Dividend King, a group of companies that have raised dividends for at least 50 years [2][4] - The company has a strong cash profile, a diverse portfolio, and a significant pipeline, which supports its commitment to continue raising dividends [2][5] Business Structure - Following the spin-off of its consumer health business into Kenvue, J&J is now focused solely on pharmaceuticals and medical technology [4] - J&J has 26 products or platforms that each generate over $1 billion in sales, which are key drivers of its revenue and cash flow [4] Financial Performance - In 2024, J&J allocated $17 billion for research and development (R&D) while paying out $11.8 billion in dividends [5] - The company aims to become a leading oncology player with a target of $50 billion in sales, driven by products like Darzalex and Carvykti [6] Growth Potential - J&J's recent acquisition of Intra-Cellular Therapies for $14.6 billion adds the antipsychotic drug Caplyta to its portfolio, which is expected to reach $5 billion in sales [6] - The medical technology segment, particularly in robotic surgery and cardiovascular solutions, is identified as a major growth area [6] Investment Appeal - J&J is recognized as one of the largest healthcare companies in the U.S., characterized by disciplined R&D investment, steady cash generation, and a robust pipeline [7] - The stock currently yields 2.9%, making it an attractive option for dividend investors [7]

Johnson & Johnson FY Conference Summary Company Overview - **Company**: Johnson & Johnson (NYSE: JNJ) - **Date of Conference**: September 24, 2025 - **Speaker**: Tom Cavanaugh, Company Group Chairman, Johnson & Johnson Innovative Medicine North America Key Points Business State and Growth Outlook - Johnson & Johnson is entering a new era of growth in the innovative medicine sector, overcoming the loss of exclusivity of its major asset, Stelara [4][5] - The company anticipates a compound annual growth rate (CAGR) of 5% to 7% through the remainder of the decade, with confidence leaning towards the upper range of this projection [6][7] Recent Product Launches and Pipeline - Recent approvals include TAR 200 for bladder cancer and Caplyta for adjunctive major depressive disorder, with the latter expected to significantly contribute to growth [5][6] - Tremfya, launched for inflammatory bowel disease (IBD), is projected to exceed $10 billion in sales, driven by its unique administration method and strong market reception [19][20] - Rybrevant for non-small cell lung cancer is also expected to reach over $5 billion in peak sales, supported by positive clinical data [21][22] Market Dynamics and Policy Environment - The company has raised its guidance amidst various macroeconomic challenges, indicating confidence in its ability to navigate policy uncertainties [11][12] - Johnson & Johnson is committed to $55 billion in U.S. manufacturing, aligning with government initiatives to boost domestic production [13][14] Oncology and Immunology Insights - Darzalex, a foundational therapy for multiple myeloma, is expected to continue its growth trajectory, with significant survival rate improvements reported [41][42] - The company is optimistic about the potential of Carvykti, a CAR-T therapy, to achieve over $5 billion in peak sales, especially with recent data showing long-term remission in patients [43][46] Neuroscience Developments - Spravato has shown strong growth, with a unique profile that allows for rapid efficacy in treatment-resistant depression [71][72] - Caplyta is anticipated to become a $5 billion asset, with a focus on its efficacy and minimal side effects compared to traditional treatments [74][77] Research and Development Strategy - Johnson & Johnson emphasizes a strong commitment to R&D, focusing on oncology, immunology, and neuroscience, while leveraging AI for efficiency [82] - The company is open to M&A opportunities, particularly in adjacent therapeutic areas, to enhance its portfolio [83] Future Opportunities - The company is exploring new modalities such as cell therapy and gene editing, with a focus on disease area strategies rather than specific modalities [85] - There is a strong emphasis on integrating MedTech capabilities with pharmaceutical innovations, as seen with TAR 200 [89] Additional Insights - The company is actively addressing the disconnect between market expectations and its growth potential, particularly in oncology and neuroscience [58][78] - Johnson & Johnson is committed to transparency in pricing and reducing healthcare costs through policy engagement and reform [15][16] This summary encapsulates the key insights and strategic directions discussed during the conference, highlighting Johnson & Johnson's robust growth outlook and innovative product pipeline.

Johnson & Johnson (NYSE:JNJ) is included among the 12 Best Dividend Paying Stocks to Buy Now. Johnson & Johnson’s (JNJ) Dividend Growth Record Strengthens its Role in Dividend Paying Stocks Johnson & Johnson (NYSE:JNJ) is a major player in the pharmaceutical and medical device industries, with a recent market value close to $425 billion. The company is also showing growth, as second-quarter revenue increased 5.8% from the previous year and earnings rose 18%. Until 2023, Johnson & Johnson (NYSE:JNJ) oper ...

Core Concept - The concept of a wide moat refers to companies with strong, lasting competitive advantages that protect them from competition and enable long-term profitability [1] Group 1: Companies with Wide Moats - Recognized companies with wide moats include Microsoft Corporation, Johnson & Johnson, S&P Global Inc., and NIKE, Inc., all operating in industries with significant barriers to entry [2] - Companies with wide economic moats benefit from brand strength, cost advantages, network effects, regulatory barriers, and economies of scale, making it difficult for competitors to erode their market share [3] Group 2: Investment Rationale - Investing in wide-moat businesses is seen as a strategy for steady, long-term returns, as these companies tend to be more resilient during economic downturns compared to those in highly competitive industries [4] - Wide-moat companies typically produce steady cash flows, navigate market volatility effectively, and deliver value to shareholders through dividends and stock price growth [5] Group 3: Microsoft Corporation - Microsoft holds a dominant position due to its ecosystem of software, cloud services, and enterprise solutions, creating high switching costs for customers [7] - In fiscal 2025, Microsoft's AI business surpassed a $13 billion annual revenue run rate, growing 175% year over year, while cloud revenues exceeded $168 billion with 23% growth [8] - Microsoft achieved unprecedented scale with commercial bookings exceeding $100 billion for the first time, demonstrating strong enterprise penetration and significant expansion in large contracts [9] - The company generated outstanding cash flow in fiscal 2025, showcasing its financial strength and ability to invest in AI infrastructure [10] - Microsoft is uniquely positioned to capitalize on the multi-trillion-dollar AI opportunity while maintaining financial stability and robust shareholder returns [11] Group 4: Johnson & Johnson - Johnson & Johnson enjoys a wide moat in healthcare due to its diversified portfolio, trusted brand, and extensive R&D capabilities, with regulatory barriers further protecting its position [12] - The company has over 275 subsidiaries, indicating strong diversification that helps it withstand economic cycles [13] - JNJ expects to generate more than $57 billion in sales in its Innovative Medicines segment in 2025, with anticipated growth of 5-7% from 2025 to 2030 [15] Group 5: S&P Global - S&P Global benefits from an economic moat driven by brand strength, regulatory influence, and data-driven services, with its credit rating business being essential for various market participants [16] - The company's proprietary financial data and analytics services provide indispensable tools, ensuring customer reliance and giving it pricing power [17] - The growing demand for business information services and risk mitigation is expected to drive market growth for S&P Global [18][19] Group 6: NIKE, Inc. - NIKE is the global leader in athletic footwear and apparel, with unmatched scale and cultural dominance, despite facing revenue challenges in fiscal 2025 [20] - The company maintains strong brand equity through powerful athlete partnerships and cultural relevance, positioning it for sustainable expansion [21] - NIKE is executing its "Win Now" strategy to restore brand momentum and streamline its portfolio, focusing on performance-led categories and women's sportswear [22] - The company is enhancing its integrated marketplace by strengthening NIKE Direct and expanding through strategic partnerships with Amazon and Urban Outfitters [23]